SAMSCA (TOLVAPTAN)
Live / Registered — Registered (as of 01 Nov 2022)
What this means for you
Registered since 01 Nov 2022. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 01 Nov 2028: the §8 declaration of use).
Record
- Serial number
- 97022225
- Registration number
- 6888096
- Mark type
- Design + words
- Filed
- 10 Sept 2021
- Published for opposition
- 16 Aug 2022
- Registered
- 01 Nov 2022
- Next maintenance filing
- §8 declaration of use, due by 01 Nov 2028 (grace period to 01 May 2029)
- Attorney of record
- Scott S. Havlick
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of hyponatremia, in patients with Syndrome of Inappropriate Antidiuretic Hormone (SIADH), heart failure and cirrhosis, namely, Tolvaptan
Owner
- Otsuka Pharmaceutical Co., Ltd., Chiyoda-ku, Tokyo,, JP
- Otsuka Pharmaceutical Co., Ltd., Chiyoda-ku, Tokyo,, JP
- Otsuka Pharmaceutical Co., Ltd., Chiyoda-ku, Tokyo,, JP
Prior registrations
Prosecution history
- 01 Nov 2022 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 01 Nov 2022 — REGISTERED-PRINCIPAL REGISTER
- 16 Aug 2022 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 16 Aug 2022 — PUBLISHED FOR OPPOSITION
- 27 Jul 2022 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 12 Jul 2022 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 09 Jul 2022 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 08 Jul 2022 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 08 Jul 2022 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 28 Apr 2022 — NOTIFICATION OF PRIORITY ACTION E-MAILED
- 28 Apr 2022 — PRIORITY ACTION E-MAILED
- 28 Apr 2022 — PRIORITY ACTION WRITTEN
- 25 Apr 2022 — ASSIGNED TO EXAMINER
- 20 Oct 2021 — NOTICE OF DESIGN SEARCH CODE E-MAILED
- 19 Oct 2021 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED